Author

C. Braley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

O. Reizes· 4 shared E. Esakov· 3 shared J. Lathia· 3 shared C. Michener· 2 shared G. Dey· 2 shared L. Chambers· 2 shared P. G. Rose· 2 shared A. Hajjar· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

O. Reizes

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

LCK Regulates Homologous Recombination DNA Repair Identifying a New Therapeutic Target for Sensitizing PARP Inhibitors in HR Proficient Ovarian Cancer

G. Dey, R. Bharti, C. Braley, R. Alluri, E. Esakov, K. Crean-Tate, K. McCrae, A. Joehlin-Price, P. G. Rose, J. Lathia, Z. Gong, O. Reizes

This study identifies LCK's role in HR repair in ovarian cancer, showing its inhibition sensitizes HR-proficient tumors to PARP inhibitors.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Pretreatment with LCK Inhibitors Chemosensitizes Cisplatin-Resistant Endometrioid Ovarian Tumors

K. K. Crean-Tate, C. Braley, G. Dey, E. Esakov, C. Saygin, A. Trestan, D. J. Silver, S. M. Turaga, E. V. Connor, R. Debernardo, C. M. Michener, P. G. Rose, J. Lathia, O. Reizes

This study shows that pretreatment with LCK inhibitors makes cisplatin-resistant endometrioid ovarian tumors more sensitive to cisplatin, improving cell viability and tumor growth inhibition.

bioRxiv · Jun 18, 2020Cancer Biology

Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

L. Chambers, E. L. Esakov, C. Braley, L. Trestan, Z. Alali, D. Bayik, J. Lathia, N. Sangwan, P. Bazeley, A. S. Joehlin-Price, M. Dwidar, A. Hajjar, P. P. Ahern, J. Claesen, P. Rose, , O. Reizes

This study shows that antibiotic treatment disrupts the gut microbiome, leading to increased resistance to cisplatin in ovarian cancer models.

bioRxiv · Jun 16, 2020 · PreprintCancer Biology

Use of Transabdominal Ultrasound for the Detection of Intra-Peritoneal Tumor Engraftment and Growth in Mouse Xenografts of Epithelial Ovarian Cancer

L. Chambers, E. Esakov, C. Braley, M. AlHilli, C. Michener, O. Reizes

This study evaluates transabdominal ultrasound (TAUS) for detecting intra-peritoneal tumor growth in mouse xenografts of epithelial ovarian cancer, showing it can detect tumors as small as 2 mm and as early as seven days post-injection.

bioRxiv · Jan 20, 2020Cancer Biology